Bicycle Therapeutics gets FDA Orphan Drug Designation for pancreatic cancer therapy
Bicycle Therapeutics announced that nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer, ahead of expected phase 2 trial updates and the anticipated initiation of a radioligand trial in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed